Overview

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Status:
Not yet recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Nanjing Sanhome Pharmaceutical, Co., Ltd.